Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Dr. Dan Sperling As a radiologist specializing in prostate cancer diagnosis and treatment, I’m writing to share a fear I often hear from my patients. “Will this treatment affect my sex life?” This ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer ...

A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

MacroGenics stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE stock now.